Author(s):
Swati U. Kolhe, Rohit D. Nalawade, Swapnil S. Lad
Email(s):
rohitnalawade712@gmail.com , ladswapnil6995@gmail.com
DOI:
10.52711/2231-5659.2024.00054 
Address:
Swati U. Kolhe1, Rohit D. Nalawade2*, Swapnil S. Lad3*
1Faculty, Department of Pharmacology, AISSMS College of Pharmacy, Pune - 411001, Maharashtra, India.
2,3M. Pharm Research Scholars, Department of Pharmacology, AISSMS College of Pharmacy, Pune - 411001, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 4,
Year - 2024
ABSTRACT:
Introduction: A significant risk factor for cardiovascular illnesses is hyperlipidemia, which is characterized by high blood lipid levels. Innovative pharmaceuticals made from organic materials like plants are desperately needed to treat hyperlipidemia. Compared to synthetic medications, these possible plant-based remedies might provide a therapeutic option that is both economical and free of adverse effects. We performed an experiment utilizing an acute hyperlipidemia model to assess the hypolipidemic efficacy of an aqueous flower extract (FE).
Methods: We used 30 female Wistar rats for the experiment, which were split into five groups (n = 6 each) for each model. The standard employed was fenofibrate (250 mg/kg p.o.), and Triton X-100 was used to generate hyperlipidemic activity in the rats. Our study evaluated the effectiveness of an aqueous flower extract over a 15-day period at dosages of 250 and 500 mg/kg (p.o.). Several parameters were used to evaluate the hypolipidemic activity. Results: In the study, the flower extract treatment demonstrated significant positive effects. It notably reduced cholesterol, triglycerides, and LDL levels induced by Triton X-100, indicating its potential in lowering elevated lipid levels. Furthermore, the extract substantially increased HDL levels. However, it did not have a significant impact on VLDL levels. Conclusion: Our study suggests that the flower extract (FE) has the potential to act as a hypolipidemic agent, possibly attributed to its capability to inhibit cholesterol synthesis and intestinal lipid absorption. The FE is abundant in phytochemicals such as flavonoids and phenols, which could be contributing factors to its hypolipidemic effect.
Cite this article:
Swati U. Kolhe, Rohit D. Nalawade, Swapnil S. Lad. Evaluation of Hypolipidemic Activity of Aqueous Flower Extract of Adenocalymma alliaceum in Triton X-100 Induced Experimental Model of Rats. Asian Journal of Research in Pharmaceutical Sciences. 2024; 14(4):339-4. doi: 10.52711/2231-5659.2024.00054
Cite(Electronic):
Swati U. Kolhe, Rohit D. Nalawade, Swapnil S. Lad. Evaluation of Hypolipidemic Activity of Aqueous Flower Extract of Adenocalymma alliaceum in Triton X-100 Induced Experimental Model of Rats. Asian Journal of Research in Pharmaceutical Sciences. 2024; 14(4):339-4. doi: 10.52711/2231-5659.2024.00054 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2024-14-4-2
REFERENCES:
1. Lad SS, Kolhe SU, Devade OA, Patil CN, Nalawade RD, Mansabdar AP. Hyperlipidaemia: A Review of Literature. Research Journal of Pharmacology and Pharmacodynamics. 2023; 15(3): 127-132. doi:10.52711/2321-5836.2023.00023
2. Chenni A, Yahia DA, Boukortt FO, Prost J, Lacaille-Dubois MA, Bouchenak M. Effect of aqueous extract of Ajuga iva supplementation on plasma lipid profile and tissue antioxidant status in rats fed a high-cholesterol diet. J Ethnopharmacol. 2007; 109(2): 207-213. doi:10.1016/j.jep.2006.05.036
3. Goff DC, Gerstein HC, Ginsberg HN, et al. Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. American Journal of Cardiology. 2007; 99(12suppl.). doi:10.1016/j.amjcard.2007.03.002
4. Farmer JA. Diabetic Dyslipidemia and Atherosclerosis: Evidence from Clinical Trials. Curr Atheroscler Rep. 2007; 9(2): 162-168. doi:10.1007/s11883-007-0013-8
5. Fredrickson DS, Lees RS. A system for phenotyping hyperlipoproteinemia. Circulation. 1965; 31(3): 321-327. doi:10.1161/01.cir.31.3.321
6. Ames RP. Hyperlipidemia in hypertension: causes and prevention. Am Heart J. 1991; 122: 1219-1224. doi:10.1016/0002-8703(91) 90943-c
7. Nelson RH. Hyperlipidemia as a Risk Factor for Cardiovascular Disease. Primary Care - Clinics in Office Practice. 2013; 40(1): 195-211. doi:10.1016/j.pop.2012.11.003
8. Lad SS, Kolhe SU. Evaluation of antihyperlipidemic potential of aqueous corm extract of Colocasia esculenta in experimental model of rats. Pharmacological Research - Modern Chinese Medicine. 2023; 9: 100307. doi:10.1016/j.prmcm.2023.100307
9. Camden MT, Jan FD, Durwood BR. Effect of Mansoa alliacea (Bignonaceae) leaf extract on embryonic and tumorigenic mouse cell lines. Journal of Medicinal Plants Research. 2015; 9(29): 799-805. doi:10.5897/jmpr2015.5823
10. Sudirga SK, Ketut Ginantra I, Darmayasa IBG. Antifungal activity of leaf extract of Mansoa alliacea against Colletotrichum acutatum the cause of anthracnose disease on chili pepper. In: IOP Conference Series: Earth and Environmental Science. Vol 347. Institute of Physics Publishing. 2019. doi:10.1088/1755-1315/347/1/012058
11. Ameenabee S, Lakshmana Rao A, Suguna Rani P, et al. Phytochemical and In-Vitro Evaluation of Anti-oxidant Activity of Mansoa alliacea Leaves. Acta Scientific Pharmaceutical Sciences. 2020; 4: 3-7.
12. Dintakurthi P, Panda SP, Prasanth DSNBK, et al. Anthelmintic activity of Mansoa alliacea against Pheretima posthuma: In vitro and In silico approach. Article in Thai Journal of Pharmaceutical Sciences. 2020; 44(3): 186-196. http://www.tjps.pharm.chula.ac.
13. Srinivasan MR, Srinivasan K. Hypocholesterolemic efficacy of garlic-smelling flower Adenocalymma alliaceum Miers. in experimental rats. Indian J Exp Biol. 1995; 33(1): 64-66.
14. Zoghbi MDGB, Oliveira J, Guilhon GMSP. The genus Mansoa (Bignoniaceae): A source of organosulfur compounds. Revista Brasileira de Farmacognosia. 2009; 19(3):795-804. doi:10.1590/S0102-695X2009000500025
15. Chutia D, Tyagi CK, Bhuyan NR, Shah SK. In vivo and in vitro Hyperglycaemic Screening of Adenocalymma alliaceum Miers, A Promising Herb. Indian Journal of Pharmaceutical Education and Research. 2022; 56(4): S713-S724. doi:10.5530/ijper.56.4s.217
16. Saleem U, Riaz S, Ahmad B, Saleem M. Pharmacological Screening of Trachyspermum ammi for Antihyperlipidemic Activity in Triton X-100 Induced Hyperlipidemia Rat Model. Pharmacognosy Res. 2017; 9: S34-S40. doi:10.4103/pr.pr_37_17
17. Bian Z, Guo Y, Ha B, Zen K, Liu Y. Regulation of the Inflammatory Response: Enhancing Neutrophil Infiltration under Chronic Inflammatory Conditions. The Journal of Immunology. 2012; 188(2): 844-853. doi:10.4049/jimmunol.1101736
18. Parwin A, Najmi AK, Ismail MV, Kaundal M, Akhtar M. Protective effects of alendronate in Triton X-100-induced hyperlipidemia in rats. Turkish Journal of Gastroenterology. 2019; 30(6): 557-564. doi:10.5152/tjg.2019.18076
19. Lad SS, Kolhe SU, Devade OA, Patil CN, Nalawade RD, Rode MR. A Review on Medicinal properties of Colocasia esculenta Linn. Research Journal of Pharmacology and Pharmacodynamics. 2023; 15(3): 2321-5836. doi:10.52711/2321-5836.2023.00026
20. R C Agarwal, S P Singh, R K Saran, et al. Clinical trial of gugulipid--a new hypolipidemic agent of plant origin in primary hyperlipidemia. Indian J Med Res. 1986; 84: 626-634.
21. Abu-Ghunmi L, Badawi M, Fayyad M. Fate of triton X-100 applications on water and soil environments: A review. J Surfactants Deterg. 2014; 17(5): 833-838. doi:10.1007/s11743-014-1584-3
22. Murphy MG, Nfigrel R, Ailhaud G. Lipoprotein lipase and monoacylglycerol lipase activities during maturation of OB, preadipocytes. Vol 664.; 1981.
23. Krauss RM, Herbert PN, Levy RI, Fredrickson DS. Further Observations on the Activation and Inhibition of Lipoprotein Lipase by Apolipoproteins. http://circres.ahajournals.org/
24. Ling. A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations. Cardiol Res. Published online 2013. doi:10.4021/cr270w
25. Del Bas JM, Fernández-Larrea J, Blay M, et al. Grape seed procyanidins improve atherosclerotic risk index and induce liver CYP7A1 and SHP expression in healthy rats. The FASEB Journal. 2005; 19(3): 1-24. doi:10.1096/fj.04-3095fje